In episode 15 of Cutaneous Miscellaneous, our host Nicholas Brownstone, MD, chats with Michael Cameron, MD, Assistant Clinical Professor of Dermatology at Mount Sinai and founder of Cameron Dermatology, a private practice in New York City. The episode begins with board review and practical tips on JAK inhibitors. Dr Cameron discusses the lessons learned from the ORAL Surveillance trial and focuses on safety of JAK inhibitor use in dermatology patients. He discusses how to counsel patients on the potential safety concerns with JAK inhibitors and offers his thoughts on what kinds of questions could be on the board exam concerning these novel therapies. In the main part of the episode, Dr Cameron provides his experience on starting his own private practice and gives advice on how to successfully start one. If you are considering starting a private practice or are just interested in hearing about the process, this is an episode you can’t miss! FREE Biologics and JAK/TYK2 Inhibitors in Dermatology Quick Reference Chart https://dermsquared.com/resources/biologics-and-jak-charts Dr. Cameron’s article, “JAK Inhibitor Safety: What Did ORAL Surveillance Really Teach Us?” https://www.hmpgloballearningnetwork.com/site/thederm/cover-story/jak-inhibitor-safety-what-did-oral-surveillance-really-teach-us

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related